中/EN: 中文繁體 English

Investor Relations
IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
Corporate

Press Releases

2022

Please select

AUG
24

The United Laboratories International Holdings Limited Announces 2022 Interim Results, Ebitda up 8.0% to Rmb1,141 Million, Interim Dividend up 25.0% to RMB5 Cents Per Share, Sales Volume of Insulin Series Grows Steadily, Insulin Degludec/Insulin Aspart Injection Receive Clinical Trial Approval

MAR
24

The United Laboratories International Holdings Limited Announces 2021 Annual Results, Continuous Improvement in Profitability, Proposed Final Dividend and Special Dividend totaled RMB0.1 Per Share